Ayala Pharmaceuticals, Inc.
ADXS•OTC
Ayala Pharmaceuticals, Inc.
ADXS•OTC
Mkt Cap$25.71M
Sentiment
Phase 1 · Company Overview
Step 1: Overview
What the company does, where it operates, and who runs it.
Overview for Ayala Pharmaceuticals, Inc.
Industry:Biotechnology
Sector:Healthcare
CEO:Kenneth A. Berlin
Description:Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Address:9 Deer Park Drive, Monmouth Junction, NJ, US
Step 2: Infographics
Visual summary of the business at a glance.
Phase 2 · FRC Research
Step 3: Media
Videos and interviews covering the company.
Phase 3 · Financial Data
Step 4: Stock Data
Price chart, volume, and trading data.
ADXS Stock Price
Step 5: Fair Value
What FRC thinks the stock is worth vs. the current price.
Step 6: Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Step 7: Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Step 8: Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Step 9: Financial Statements
Income statement, balance sheet, and cash flow statements.
Phase 4 · Peer Comparison
Step 10: Comparables
List of peer companies in the same industry.
Phase 5 · Ownership & News
Step 12: Institutional Ownership
Which funds and firms own the stock.
Step 13: Insider Trading
Recent buying and selling by company executives.
Step 14: Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
Step 15: News
Latest headlines and market coverage.
News
Latest Market News